他克莫司治疗儿童肾小球疾病的个体化用药专家共识  

Expert consensus on individualized dosing of tacrolimus for pediatric glomerular diseases

作　　者：中国药理学会治疗药物监测研究专业委员会 广东省药学会 《中国实用儿科杂志》编辑委员会 莫小兰 黄凌斐[3] 赵一鸣[4] 曹娟[5] 谢萍 王晓玲[4] Division of Therapeutic Drug Monitoring,Chinese Pharmacological Society;Guangdong Pharmaceutical Association;Editorial Committee of Chinese Journal of Practical Pediatrics;MO Xiao-lan;WANG Xiao-ling

机构地区：[1]不详 [2]广州医科大学附属妇女儿童医疗中心 [3]浙江大学医学院附属儿童医院 [4]首都医科大学附属北京儿童医院 [5]江西省儿童医院

出　　处：《中国实用儿科杂志》2025年第1期1-12,共12页Chinese Journal of Practical Pediatrics

摘　　要：他克莫司是儿童肾小球疾病治疗中被广泛应用的免疫抑制剂,由于药代动力学、药效动力学的个体差异大,精准用药面临困境。国内外尚缺乏他克莫司治疗儿童肾小球疾病的个体化用药指引。该共识结合国内外最新研究进展和临床实践经验,从他克莫司在儿童肾小球疾病中的应用、血药浓度监测、药物基因检测和药学监护几方面进行总结,以期协助医师、药师开展个体化用药,提高患者满意度。Tacrolimus is a widely used immunosuppressant in the treatment of pediatric glomerular diseases.However,precision dosing presents a challenge due to significant individual differences in pharmacokinetics and pharmacodynamics.Currently,there are no guidelines for individualized dosing of tacrolimus in the treatment of pediatric glomerular diseases,either domestically or internationally.With the aim of assisting physicians and pharmacists in implementing individualized dosing and improving patient satisfaction,the consensus,summarizes the application of tacrolimus in pediatric glomerular diseases,its concentration monitoring,pharmacogenetic testing,and pharmaceutical care based on the latest research advancements and clinical practice experience both domestically and internationally.

关 键 词：他克莫司 儿童 肾小球疾病 个体化用药 药学监护 

分 类 号：R72[医药卫生—儿科]